US, UK Approve Roche’s $4.3bn Purchase Of Spark
December 18, 2019
3:21 pm
Swiss pharmaceuticals giant Roche said it had received the necessary approval from competition authorities to acquire US gene-therapy group Spark, after the two companies reached a multibillion-dollar deal earlier this year.
Founded in 2013, Spark Therapeutics specialises in a new and growing segment of medicine for genetic diseases such as blindness, haemophilia, and neurodegenerative conditions.
The US Federal Trade Commission (FTC) “unconditionally cleared Roche’s pending acquisition of Spark”, the Swiss company said in a statement on Monday.
“All antitrust approvals required to complete the offer have now been received,” it said, after confirming earlier Monday that Britain’s Competition and Markets …
